AstraZeneca is of all the vaccines the one with the most potential on the stock market

There are already three vaccines to immunize the population against SARS-CoV-2 that have been approved by the European Medicines Agency. The last to arrive was that of and the University of Oxford. On Friday, the team behind this latest vaccine announced that their creation appears to be effective against the so-called British strain, although the results of their research have yet to be published in one of those peer-reviewed scientific journals. At the same time, in Spain it was decided that because of the risk involved; but that doesn’t seem to deter investors.

The British pharmaceutical company is a behemoth that is worth more than 100,000 million euros on the stock market, and its shares are the ones that seem to have the most travel on the market for the coming months -among a selection of the six most important pharmaceutical and biotechnology companies that they have currently developed or are in the process of developing a vaccine against the coronavirus.

AstraZeneca shares are trading in the 72-pound zone and have a 28% upside potential, until reaching the target price of 92.96 pounds indicated by the consensus of investment bank analysts collected by FactSet. A figure that is close to the 93.20 pounds that the stock touched on July 20, its highest price in 2020. Even so, with all its potential, the stock has lost around 1% so far this year.

We will have to pay attention to what is happening in the United States, where AstraZeneca is carrying out a clinical trial of its vaccine for Covid-19 and expects to have the conclusions ready in the next four to six weeks, reports Bloomberg.

See also  Quote of TELEFONICA - Company - historical

The second stock with the greatest bullish potential on the stock market is that of the French firm Sanofi. Although among the large pharmaceutical companies in the race to put a vaccine on the market it is the furthest behind, since the doses are not expected to arrive until the end of 2021, the truth is that its titles have a potential run of 21.7%.

This means that at some point in the next twelve months it could reach the target price of 98.2 euros indicated by the market consensus; It is a price even higher than the 94.29 euros that it registered on July 20 of last year. Currently, Sanofi is listed in the area of ​​80 euros and its titles earn 2% so far this year.

The French company is the third largest producer of vaccines in the world and in 2020 alone it entered 5,900 million euros for producing some such as those that protect against polio, whooping cough or the common flu. But there are other very profitable flagship drugs, such as Dupixent and Lantus.

“Sanofi has taken several positive steps, with diabetes and cardiovascular investment on hold in favor of new medicines and vaccines,” writes Bloomberg Intelligence analyst Sam Fazeli. But much of its business is supported by a single drug, Dupixent, with which to treat patients with eczema (atopic dermatitis) and thanks to which they entered 3,500 million euros last year.

AstraZeneca and Sanofi are followed by Pfizer and Johnson&Johnson in terms of potential on the stock market. Pfizer shares could rise a further 17% in the next twelve months, from the $34 zone to $41.16, which is the analyst consensus target price. Its strategic association with BioNTech has paid off and its vaccine was the first with which the European Union began vaccinating its citizens at the end of December.

See also  Cruz Azul presented its reinforcements for the Clausura 2015

On the other hand, the upside potential for Johnson&Johnson shares is 11.78%, which means they could reach a valuation of $184.25 in the coming months. The market consensus figure is well above $170.48, which was the highest price for its shares in 2020. So far this year, they have risen about 4.5%.

The Janssen vaccine, a subsidiary of Johnson & Johnson, was 72% effective in preventing moderate and severe Covid-19 with a single dose, according to Bloomberg. On Thursday, the US company confirmed that it had applied to the US Food and Drug Administration (FDA) for emergency use approval for its experimental vaccine, with the aim of subjecting it to a rapid review. .

If authorized, the United States would have a third vaccine, after Pfizer and Moderna, with which to try to stop the transmission of a virus that has killed some 450,000 citizens in the North American country. According to information from Reuters published in August, the United States Government would have paid 1,000 million dollars to J&J for one hundred million doses of its vaccine.

Moderna and Novavax, at maximum and without travel

They have run out of potential on the stock market and analysts can no longer keep up with them. Moderna, which already has its vaccine on the market, is trading at record highs in the $174 area. In just one month, so far this year, its shares have risen by 67%. This is new ground for the company, as this is its first commercial product and it is already licensed for distribution in thirty countries. Moderna’s goal is to produce 1,000 million doses in 2021 and another 1,200 million doses in 2022, because as its CEO, the Frenchman Stéphane Bancel, assured, Covid is here to stay.

See also  Daniel Radcliffe, cover of a gay magazine

Novavax behaves along the same lines, probably the next vaccine to be authorized in the US and Europe. Its share price is already approaching $300, a record level, compared to $7 in January 2020. Year-to-date, they have accumulated a return of 165%. Its clinical trials are now in the final phase.

Loading Facebook Comments ...
Loading Disqus Comments ...